Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.

Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.

Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.

A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.

After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.

But the groups have yet to see any responses with AU-007 and XTX202 respectively.